UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000016007 |
|---|---|
| Receipt number | R000018513 |
| Scientific Title | A feasibility study of adjuvant therapy with UFT/Leucovorin+Oxaliplatin following curative resection for stage III colorectal cancer |
| Date of disclosure of the study information | 2014/12/19 |
| Last modified on | 2014/12/19 16:35:57 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A feasibility study of adjuvant therapy with UFT/Leucovorin+Oxaliplatin following curative resection for stage III colorectal cancer
Acronym
A feasibility study of adjuvant therapy with TEGAFOX following curative resection for stage III colorectal cancer
Scientific Title
A feasibility study of adjuvant therapy with UFT/Leucovorin+Oxaliplatin following curative resection for stage III colorectal cancer
Scientific Title:Acronym
A feasibility study of adjuvant therapy with TEGAFOX following curative resection for stage III colorectal cancer
Region
| Japan |
Condition
Condition
Colorectal cancer
Classification by specialty
| Gastrointestinal surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To consider the feasibilitiy, efficacy and safety of adjuvant treatment with a combination of UFT/LV plus oxaliplatin following curative resection of stage III colorectal cancer
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Phase II
Assessment
Primary outcomes
Treatment completion ratio
Key secondary outcomes
Disease free survival(DFS)
Overall Survival (OS)
Safety profile
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
UFT 300mg per m2 per day and LV 75mg per day for 28 days
Oxaliplatin:85mg/m2 day1,15
every 35 days for 5-cycle
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1.Histologically proven stage III colorectal cancer (Adenocarcinoma)
2. Pathological curability is A
3. Aged at the time of registration at least 20 yewas of age
4. Performance status(ECOG) :0,1
5. Adequate organ function
6. Able to start between 8 weeks after surgery
7. Able to receive oral treatment
8. Written IC
Key exclusion criteria
1. Multiple malignancies within five years
2. Serious complications
3. Peripheral neuropathy
4.Serious diarrhea
5. Serious drug allergy
6. Positive for HBs antigen and HCV antibody
7. Women who are pregnant, lactating, or wish to become pregnant
8. Any other cases who are regarded as inadequate for study enrollment by the investigator
Target sample size
74
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Hiroyuki Kuwano |
Organization
Gunma University Graduate School
Division name
Department of General Surgical Science
Zip code
Address
3-39-22 Showa-machi, Maebashi-shi, Gunma
TEL
027-220-8224
hkuwano@gunma-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Soichi Tsutsumi |
Organization
Gunma University Graduate School
Division name
Department of General Surgical Science
Zip code
Address
3-39-22 Showa-machi, Maebashi-shi, Gunma
TEL
027-220-8224
Homepage URL
gundai1geka@gmail.com
Sponsor or person
Institute
Gunma University Graduate School
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2014 | Year | 12 | Month | 19 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2014 | Year | 11 | Month | 26 | Day |
Date of IRB
Anticipated trial start date
| 2014 | Year | 11 | Month | 26 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2014 | Year | 12 | Month | 19 | Day |
Last modified on
| 2014 | Year | 12 | Month | 19 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018513
